Found: clinical biomanufacturing facilities and non-vaccine companies.11 Not-for- profit initiatives, like the Vaccine

Found: ), the COVID-19 infection study and the national serology platform (closed March 2023) and the Vaccine

Found: UKRI chief executive Sir Mark Walport described the Vaccine Manufacturing and Innovation Centre as

Found: surrender of unused fund ing including for Advanc ed Research and Invention Agency (ARIA), Net Zero and Vaccine

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the decision of VMIC UK Services Ltd to sell the Vaccines Manufacturing and Innovation Centre on the UK's vaccine manufacturing capabilities.

Answered by Will Quince

The decision to sell the Vaccine Manufacturing and Innovation Centre (VMIC UK Ltd) was made by VMIC UK Ltd's Board of Directors. The facility was subsequently sold to Catalent. Once completed, it is intended that the facility will be capable of producing a range of therapeutics and vaccines.

Over £405 million has been invested to strengthen United Kingdom manufacturing infrastructure to ensure a robust response to COVID-19 and potential future health emergencies and we have ambitious plans to invest more into the vaccine ecosystem and supply chain. Officials continue to engage with industry stakeholders to understand the wider landscape and implications for vaccine development and manufacturing in the UK.

Question to the Department for Science, Innovation & Technology:

To ask His Majesty's Government what evidence they have received about the impact of the loss of the Vaccines Manufacturing and Innovation Centre following its sale.

Answered by Viscount Camrose - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)

The decision to sell the Vaccine Manufacturing and Innovation Centre was made by VMIC UK Ltd's Board of Directors. The facility was subsequently sold to Catalent. Once completed, it is intended that the facility will be capable of producing a range of therapeutics and vaccines.

Officials regularly engage with industry stakeholders to understand the wider landscape and implications for vaccine development and manufacturing in the UK and will continue to do so.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the implications the sale of the Vaccines Manufacturing And Innovation Centre (VMIC) near Oxford for the UK’s long-term investment in vaccine manufacturing; and how the disposal of the VMIC will contribute to the preparedness of the UK for future pandemics, particularly in view of the experiences of COVID-19 pandemic.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The decision to sell the Vaccine Manufacturing and Innovation Centre was made by VMIC UK Ltd.’s Board of Directors, with the facility being subsequently sold to Catalent. Once completed, it is intended that the facility will be capable of producing a range of therapeutics and vaccines.

Officials regularly engage with industry stakeholders to understand the wider landscape and implications for vaccine development and manufacturing in the United Kingdom and will continue to do so. Officials are also working across Government to review lessons learned from the COVID-19 pandemic and prepare for future health emergencies.

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, how much revenue was raised for the Exchequer by the sale of the Vaccines Manufacturing Innovation Centre; and whether those funds will be reinvested into life sciences manufacturing capabilities in the UK.

Answered by George Freeman

The Vaccine Taskforce granted funding to VMIC Ltd to support development of the Vaccine Manufacturing and Innovation Centre, a vaccine research and manufacturing facility in Harwell.

In late 2021, VMIC UK Ltd's Board of Directors made the decision to sell the facility through a competitive process. In April 2022, the facility was sold to Catalent. VMIC Ltd subsequently entered a voluntary liquidation.

The courts appointed liquidators to act on behalf of creditors and this process is under way. It is not possible to comment on the question of revenue raised while the liquidation process is ongoing.

Found: recoveries); • £120 million from Advanced Research and Invention Agency; and • £79 million from the Vaccine

Found: In parallel, a new animal vaccine manufacturing and innovation centre is being established at the

Found: In parallel, a new animal vaccine manufacturing and innovation centre is being established at the Pirbright

Found: one year334Later than one year and not later than five years786Total1,120Disposal of Assets owned by Vaccine

Found: resulting in a new UK Vaccines Network for outbreak pathogen vaccines, and my co-founding of a new UK Vaccine